32 results about "Lower limb ischemia" patented technology

The invention relates to a biodegradable traditional Chinese medicine slow-release implant for lower limb ischemia revascularization and its preparation. It consists of hollow tubes, which are single or double layered. The material of the tube is a biodegradable polymer loaded with traditional Chinese medicine that promotes angiogenesis, and the biodegradable polymer is polycaprolactone, pullulan polysaccharide, polylactic acid, polyglycolic acid, polylactic acid-polyethylene glycol Acid copolymer, polycaprolactone-polylactic acid copolymer, polydioxane, hydroxypropylmethylcellulose, collagen, alginic acid or chitosan and its derivatives. The mass ratio of the traditional Chinese medicine to the biodegradable polymer is 0.1-500mg: 5-1000mg. It is puerarin, salidroside, icariin, paeoniflorin, danshensu, tanshinone, Dalbergia root water extract or Trichosanthes fruit water extract. The invention can promote the formation of new blood vessels in ischemic lower limbs and improve the blood perfusion of lower limbs. The preparation method of the invention is simple and easy to operate.

Devices and methods for perfusing a patient's vasculature are provided. The device preferably includes a cannula with a port and a retractable sheath disposed over the port of the cannula. When the cannula is positioned within the patient's vasculature, the retractable sheath may be retracted to expose the port to divert blood flow towards another portion of the patient's vasculature, for example, to prevent ischemia of the patient's lower extremities. The device may be used during heart surgery, percutaneous heart or circulatory procedures, or other cardiac interventional procedures and may be used in conjunction with another device such as an extracorporeal membrane oxygenation (“ECMO”) machine.

In a method for treating an aortic arch disease, after an intraoperative stent is expanded in an aorta and at least one arch branch vessel, and before the vessel is exactly anastomosed with an incision, by blocking a thoracic aorta between the incision and an arch branch vessel closest to the incision, the intraoperative stent in the thoracic aorta is also blocked, so that blood is prevented from flowing from the incision, and a proximal orifice of the intraoperative stent, and the low body perfusion may be recovered in advance, thereby reducing the circulatory arrest time of the low body perfusion and reducing the time of ischemia of visceral organs and lower limbs of a patient. Meanwhile, the flow of a cerebral perfusion through the right axillary artery may be recovered to a normal flow in advance, and the time of ischemia of the brain of the patient is reduced.

The invention discloses a metal polyphenol microcapsule carrier with ROS (reactive oxygen species) responsiveness and metal ion slow-release function and a preparation method. The preparation method comprises the following steps of (1) dissolving calcium chloride dehydrate into water, so as to obtain a solution I; dissolving calcium carbonate anhydrous into water, so as to obtain a solution II; adding the solution II into the stirred solution I, precipitating, washing by water, and centrifuging; (2) adding water into the precipitate, adding liquid prepared from polyphenol, and uniformly mixing; adding an aqueous solution of metal ions, uniformly mixing, adding an aqueous solution of 3-(N-morpholine)propanesulfonic acid, uniformly mixing, centrifuging, washing by water, and centrifuging, soas to obtain precipitate; (3) repeating the step (2); (4) adding an aqueous solution of EDTA (ethylene diamine tetraacetic acid), uniformly mixing, standing, and centrifuging, so as to obtain precipitate; (5) repeating the step (4); (6) washing the precipitate by water; mixing and suspending in water, and freeze-drying. Proofed by experiment, the metal polyphenol microcapsule carrier has good ability of clearing H2O2 (hydrogen peroxide); proofed by a mouse lower limb ischemia model, the metal polyphenol microcapsule carrier has the effect of accelerating generation of micro-blood vessels.

The invention discloses a novel biological material with controlled release of nitrogen monoxide under catalysis of an enzyme, as well as a preparation method and application thereof. The novel biological material with the controlled release of the nitrogen monoxide under the catalysis of the enzyme is prepared by connecting a nitrogen monoxide donor compound with stable glycosylation with a natural polymer, namely chitosan through covalent bonds. The material has good processability and can be prepared into injectable solutions, thin films, porous supports, electrostatic spinning fiber films and other various products. The CS-NO and a composite material thereof can be used for treating diabetic lower limb ischemia, skin injures and myocardial infarction disease. As the nitrogen monoxide can be released in a controlled manner according to requirements, the material shows a great effect in treatment.

The invention discloses an umbilical artery para-aortic stem cell injection for treating an ischemic disease and a preparation method thereof. The injection comprises suspended umbilical artery para-aortic stem cells and a solvent. The solvent may be platelet-rich umbilical cord plasma or PBS for injection containing human serum albumin. The preparation method comprises the steps of after umbilical artery tissue culture, deriving the artery para-arterial stem cells, enzymatically digesting to obtain single umbilical artery para-aortic stem cell, washing twice with PBS, and then gently mixing with the solvent to obtain the umbilical artery para-arterial stem cell injection. The cells are taken from a medical waste umbilical cord and have the advantages of easy separation, rapid proliferation and low immunogenicity. The PBS containing the 5% human serum albumin or the platelet-rich umbilical cord plasma resuspends the umbilical artery para-arterial stem cells to prepare the injection suspension, and the suspension is injected to significantly improve the blood supply of lower limb ischemia model mice.

The invention belongs to the technical field of medicine, and discloses a preparation method of an artificial blood vessel covered by a gene editing mesenchymal stem cell. The method comprises the steps of building a carrier of an overexpression GREM1 gene; acquiring the mesenchymal stem cell overexpressed by GREM1; jointly placing a GREM1 overexpressed mesenchymal stem cell suspension and the artificial blood vessel into a pulsatile bioreactor for culturing. According to the artificial blood vessel covered by the gene editing mesenchymal stem cell, provided by the invention, the overexpression GREM1 gene can promote mesenchymal stem cell survival, the covered mesenchymal stem cell and secretory factors thereof can inhibit posttransplant inflammation, angiogenesis is promoted, lower limb ischemia is relieved and repaired, and a new way is provided for treating ischemic diseases.

The invention discloses a method for raising water solubility of hydrogen, comprising the following steps: putting water into an aluminium bag and pretreating at 4 DEG C at the pressure of 0.4-0.8 Mpa for 6-7h; continuously blowing pure hydrogen prepared by electrolysis of water at 4 DEG C at the pressure of 0.4Mpa into water to dissolve for 2-3h; carrying out ultrasonic treatment on the above solution at 4 DEG C at pressure of 0.2Mpa under the condition of 10-30 thousands Hertz for 2-4h; and finally storing the hydrogen-containing solution at low temperature of 1-4 DEG C. When the above hydrogen-containing solution is applied on the surface of the skin, an aqueous solution containing hydrogen is conveyed through a conveyer pipe to the surface of the skin, hydrogen enters the skin through a biological membrane of the conveyer pipe, and the aqueous solution is recycled after outputted by the conveyer pipe. According to the hydrogen-containing solution, the aqueous solution is recycled but never enters human body. Thus, metabolism of patients is greatly reduced. The hydrogen-containing solution is especially suitable for disabled patients with lower limb ischemia reperfusion injury. By the preparation method, solubility of hydrogen can be greatly raised, and the effect of treating lower limb ischemia reperfusion injury is significant.

The invention discloses a lower limb rehabilitation training device and a lower limb rehabilitation training method. The device comprises an execution module, a measurement module and a control module. The execution module comprises an air inlet pump, an air outlet pump and an air bag, and the air bag is connected with the air inlet pump and the air outlet pump through air paths. The measuring module comprises a gas pressure sensor, and the gas pressure sensor is connected to the gas path. The control module comprises a controller, and the controller receives signals of the air pressure sensorto control the air inlet pump and the air outlet pump to work so as to control the air pressure in the air bag. The invention provides on-line acquisition and real-time control of an air bag pressurevalue, so that the air pressure control precision meets the set requirement. When an abnormal pressure value occurs, the abnormal pressure value can be adjusted back to a preset value allowable rangewithin a specified time. As a result, a patient can safely and effectively perform BFR training. The lower limb ischemia and the muscle injury caused by air bag pressure rise due to muscle expansionare prevented. The defect that the training effect is weakened or even invalid due to low air pressure is overcome.

In a method for treating an aortic arch disease, after an intraoperative stent is expanded in an aorta and at least one arch branch vessel, and before the vessel is exactly anastomosed with an incision, by blocking a thoracic aorta between the incision and an arch branch vessel closest to the incision, the intraoperative stent in the thoracic aorta is also blocked, so that blood is prevented from flowing from the incision, and a proximal orifice of the intraoperative stent, and the low body perfusion may be recovered in advance, thereby reducing the circulatory arrest time of the low body perfusion and reducing the time of ischemia of visceral organs and lower limbs of a patient. Meanwhile, the flow of a cerebral perfusion through the right axillary artery may be recovered to a normal flow in advance, and the time of ischemia of the brain of the patient is reduced.

The invention discloses a VA-ECMO femoral artery cannula providing lower limb blood perfusion and a catheter indwelling method. The cannula comprises a cannula body and a puncture guide core, a main cavity and a side cavity which are independent of each other are formed in the cannula body, the main cavity is of a front-back through structure, a main cavity side hole is formed in the outer side of the front end of the main cavity, the side cavity wraps the periphery of the rear end of the main cavity, a side cavity side hole is formed in the outer side of the side cavity along a same front-back straight line, an annular air bag is arranged at the position, between the main cavity side hole and the side cavity side hole, of the cannula body, and a bulging air bag is arranged at the rear end extension line position of the side cavity side hole; the annular air bag and the bulging air bag are both connected with air bag openings used for inflation and deflation. According to the invention, the structure of the femoral artery cannula is improved, lower limb blood perfusion can be met through one-time cannula indwelling, the occurrence rate of lower limb ischemia complications is effectively reduced, the operation is convenient, and the surgical risk, complexity and trauma to patients are reduced.

The invention relates to application of a lentivirus-mediated CXCR7 high expression engineered endothelial progenitor cell in treatment of ischemic diseases, discloses a nucleotide sequence shown as SEQ ID NO.1, and a recombinant virus and a transgenic cell containing the sequence. The invention also discloses application of the transgenic cell. The invention constructs the new recombinant lentivirus expressing CXCR7 and the transgenic endothelial progenitor cell containing the recombinant lentivirus, the cell has significantly improved transendothelial migration ability, and tests prove that the cell can effectively promote angiogenesis, treat diabetic diabetes caused lower limb ischemia and cerebral ischemia-reperfusion injury, and has good clinical application prospects.

The invention discloses a pelma and shank bionic pump and a use method, belonging to the technical field of pneumatic massaging. The pelma and shank bionic pump comprises a control part, an air pressure impacting part and an electric pulse stimulating part. The use method of the pelma and shank bionic pump comprises the steps of: S1, preparation, S2, air inflation, S3, electric pulse stimulation, S4, intermittence, and repetition of S2, S3 and S4. The pelma and shank bionic pump disclosed by the invention has the effects of accelerating venous return, enhancing artery blood supply, eliminating limb edema, and treating and improving lower limb ischemia symptoms.

The invention relates to a femoral artery intubation tube of a perfusion-free ischemia area during an extracorporeal circulation period and the application thereof. The femoral artery intubation tube comprises an intubation tube main body which is arranged at a blood supply end. The femoral artery intubation tube is characterized by also comprising a proximal end tube and a distal end tube which are communicated with the intubation tube main body, wherein the flow division and pressure division effect is achieved through the proximal end tube and the distal end tube; the proximal end tube and the distal end tube form an extracorporeal circulation perfusion tube of a T-shaped or Y-shaped integral structure; an included angle is formed between the proximal end tube of the Y-shaped perfusion tube and the intubation tube main body which is arranged at the blood supply end so as to distribute or regulate the perfusion blood flow. The femoral artery intubation tube of the perfusion-free ischemia area during the extracorporeal circulation period is applied to the femoral artery and is particularly suitable for long operation time of patients, the near end and far end perfusion of the femoral artery can be simultaneously ensured, and the lower limb ischemia caused by existing intubation tube is avoided; the defects of the existing arterial intubation tube and method are overcome, the requirements of the whole body perfusion of the perfusion-free ischemia area during the extracorporeal circulation period can be met, the distribution or regulation of the perfusion blood flow can be implemented, the perfusion pressure is not easy to rise, the blood leakage is not easy to cause, and the blood damage is small; the operation is convenient, the fixation is easy and reliable, the shifting is not easy to cause, and the application to the blood supply perfusion operation is wide.

The invention provides a biological material for a composite fibroblast growth factor 1. The biological material is formed by mixing a polypeptide RAD16-II, a fibroblast growth factor 1 and a solvent capable of dissolving the polypeptide RAD16-II and the fibroblast growth factor 1, wherein the amino acid sequence of the polypeptide RAD16-II is shown as SEQ ID NO:1 in a sequence table, or the polypeptide RAD16-II is a polypeptide with at least 60 percent of homology with the amino acid sequence shown as SEQ ID NO:1. A lower limb ischemia animal model is subjected to intervention treatment by using the biological material for the composite fibroblast growth factor 1, so that the movement functions of ischemic lower limbs of animals can be obviously improved, and the biological material disclosed by the invention can be applied to preparing medicines for treating the lower limb ischemia.

The invention discloses a stem cell preparation modified by a long-acting GLP-1 gene, a preparation method and application of the stem cell preparation. An in vivo experiment proves that the stem cellpreparation containing a mesenchymal stem cell modified by the GLP-1 gene and ipriflavone has a good function of regulating blood sugar, meanwhile, a urea nitrogen, urine creatinine and urinary albumin excretion rate can be lowered, and a diabetic lower limb ischemia condition and a limb necrosis degree can be obviously lowered. The stem cell preparation disclosed by the invention has a good effect when the stem cell preparation is used for treating diabetes mellitus and complications thereof.

The invention relates to bioactive polypeptide and an application thereof, which belong to the technical field of polypeptide exploitation. An amino acid sequence of the bioactive polypeptide is shownas SEQ ID NO.1. The polypeptide can promote migration and homing of injured tissues of a plurality of stem cells and differentiation of adult cells. According to the invention, angiogenesis can be promoted in myocardial ischemia and lower limb ischemia diseases, blood supply is improved, and tissue repair regeneration can be accelerated; the bioactive polypeptide can be used for skin injury, canpromote tissue repair of the skin, induce the migration, proliferation and differentiation of the stem cells of the skin, and can promote the angiogenesis and function recovery of an injured part.

The invention relates to a carotid artery and femoral artery cannula capable of reducing ischemic time of a brain or limbs and application thereof. The carotid artery and femoral artery cannula comprises a cannula body with a blood supplying end, and is characterized by also comprising a proximal artery tube and a distal artery tube which communicate with the cannula body and play roles in shunting and sharing pressure, thus forming an extracorporeal circulation plastic perfusion tube of which the whole structure is T-shaped or Y-shaped, wherein an included angle is reserved between the proximal artery tube of the perfusion tube with Y-shaped structure and the cannula body of the blood supplying end to distribute and adjust blood flow volume of perfusion. The carotid artery and femoral artery cannula is applied to a right common carotid artery to achieve systemic arterial perfusion during the extracorporeal circulation period and selective cerebral perfusion during deep hypothermic circulatory arrest, and also applied to the femoral artery to achieve systemic arterial perfusion during the extracorporeal circulation period and meanwhile avoid lower limb ischemia. Obviously, the carotid artery and femoral artery cannula is convenient to operate, strong in universality and greatly shortened in operation time, so that ischemic time of the brain or the limbs can be greatly reduced, and success rate of aortic arch surgery is improved, and thereby carotid artery and femoral artery cannula can be widely used.

The invention relates to a protein and a pharmaceutical composition for treating ischemic diseases. Specifically, it is found by the inventor that insulin-like growth factor binding protein, especially insulin like growth factor binding protein-4 (IGFBP-4) has an excellent effect on treating ischemic diseases. IGFBP-4 protein can promote vascular proliferation and the differentiation of stem cells into myocardial cells. IGFBP-4 protein also has good therapeutic and preventive effects on ischemic diseases, especially on myocardial ischemia and lower limb ischemia and has no toxic or side-effect.

The invention belongs to the technical field of traditional Chinese medicines and particularly relates to a medicament for treating lower limb ischemia, pyogenic infection and peptic ulcer and relieving pain. The traditional Chinese medicinal composition is prepared from the traditional Chinese medicinal raw materials in parts by weight: 10-20 parts of pedate pinallia jackinthepulpit rhizome, 10-20 parts of raw kusnezoff monkshood root, 25-35 parts of tuberculate speranskia herb, 10-20 parts of Chinese angelica, 10-20 parts of lignum sappan, 10-20 parts of pinellia tuber, 10-20 parts of red peony root, 10-20 parts of pericarpium zanthoxyli, 5-12 parts of radix cyathulae, 5-12 parts of angelica dahurica, 10-20 parts of cortex erythrinae, 5-12 parts of dandelion, 5-12 parts of mint, 3-8 parts of venenum bufonis, 3-8 parts of asarum, 3-8 parts of herba erigernotis and 3-8 parts of fossil fragments. By using the effects of promoting blood circulation to remove blood stasis, dredging channels, drawing out toxin and promoting tissue regeneration, arresting bleeding and treating cutaneous pyogenic infection, relieving pain and eliminating inflammation, the traditional Chinese medicinal composition disclosed by the invention can be used for treating the lower limb ischemia, treating the symptoms and the cause and quickly eliminating pains caused by peptic ulcer, suppuration and the like, so the curing effect is achieved.

The invention relates to the technical field of biological and medical technologies, in particular to a rat infrarenal abdominal aortic aneurysm model constructed through a retroperitoneal approach and a construction method. The operation is relatively simple, risks caused by the abdominal approach can be avoided, pressurized perfusion is not adopted, the perfusion time is shortened to 20 min, lower limb ischemia does not occur, the tumor formation rate is not affected, damage to blood vessels is extremely small, bleeding can be stopped through local compression after perfusion is finished, and the operation success rate is remarkably increased; The construction method comprises the following steps: S1, performing fasting for 12 hours before an operation of a rat, anesthetizing the rat with pentobarbital sodium according to 40-50mg / kg, taking a right side lying position after satisfaction of anesthesia, conventionally preserving skin, performing disinfecting, taking a connecting line from the lower part of a left side posterior axillary line costal margin to the root of a thigh as an incision with the length of 3-3.5 cm, cutting the skin, subcutaneous tissue and muscles layer by layer to see the retroperitoneal fat tissue, finding a potential gap between the peritoneum and lumbar dorsal muscles along the fat tissue, separating the gap by a cotton swab to reach the aorta abdominalis, and separating the aorta abdominalis from the inferior vena cava.

The invention discloses a method for raising water solubility of hydrogen, comprising the following steps: putting water into an aluminium bag and pretreating at 4 DEG C at the pressure of 0.4-0.8 Mpa for 6-7h; continuously blowing pure hydrogen prepared by electrolysis of water at 4 DEG C at the pressure of 0.4Mpa into water to dissolve for 2-3h; carrying out ultrasonic treatment on the above solution at 4 DEG C at pressure of 0.2Mpa under the condition of 10-30 thousands Hertz for 2-4h; and finally storing the hydrogen-containing solution at low temperature of 1-4 DEG C. When the above hydrogen-containing solution is applied on the surface of the skin, an aqueous solution containing hydrogen is conveyed through a conveyer pipe to the surface of the skin, hydrogen enters the skin through a biological membrane of the conveyer pipe, and the aqueous solution is recycled after outputted by the conveyer pipe. According to the hydrogen-containing solution, the aqueous solution is recycled but never enters human body. Thus, metabolism of patients is greatly reduced. The hydrogen-containing solution is especially suitable for disabled patients with lower limb ischemia reperfusion injury. By the preparation method, solubility of hydrogen can be greatly raised, and the effect of treating lower limb ischemia reperfusion injury is significant.

The invention discloses new application of a saturated amine compound, namely application of the saturated amine compound in preparing a medicament for treating ischemic diseases. Experiments prove that: the compound tri(2-(dimethylamino)ethyl)amine (code name TA01) can effectively participate repairing of lower limb ischemia by mobilizing endothelial progenitor cells in bone marrow. The application plays an important role in researching and developing the medicament for treating ischemic diseases, and has wide application prospect.

The invention discloses a percutaneous intervention catheter type ventricular auxiliary device, and relates to the technical field of cardiac surgery devices. The percutaneous intervention catheter type ventricular auxiliary device comprises a main drainage tube group and auxiliary drainage tube groups arranged in parallel. The problems that in the using process of a device in the traditional technology, due to implantation of an auxiliary device, lower limb circulation blood supply cannot be effectively increased, and the risk of lower limb ischemia is likely to be caused are solved; when blood is guided into a ventricle, backflow aggravation easily occurs due to the fact that blood flow vertically impacts a blood vessel wall and a valve; and two catheters are used for guiding flowing venous blood respectively, so that vascular complications and infection risks are increased.

The invention relates to an external-use moxibustion health-care product for relieving pain caused by diabetes lower limb ischemia, which is prepared by the following raw materials: rhizoma corydalis 24-36g, circium japonicum 12-18g, astragalus mongholicus 12-27g, radix aconiti carmichaeli 16-24g, radix ophiopogonis 16-24g, frankincense 8-12g, myrrh 8-12g, wormwood 300-800g, cornu cervi degelatinatum 2-5g, borneol 3-7g and appropriate amount of auxiliary materials.

The invention relates to a femoral artery intubation and indwelling catheter perfusion method capable of monitoring and increasing blood supply to lower limbs, and relates to the technical field of medical supplies. The femoral artery intubation comprises an intubation main body and a puncture tube core, the two ends of the intubation main body are provided with openings, the intubation main body is provided with a hollow inner cavity, the puncture tube core is provided with a conical tip, and a perfusion pipeline used for monitoring and increasing blood supply to the lower limb is arranged in the intubation main body, the perfusion pipeline is opened in the middle of the intubation main body, a monitoring pipe is arranged one end, entending to the outside of the intubation main body, of the perfusion pipeline, and the indwelling catheter perfusion mode is also provided. According to the femoral artery intubation and indwelling catheter perfusion method capable of monitoring and increasing blood supply to the lower limbs, the femoral artery intubation and indwelling catheter perfusion method capable of monitoring and increasing blood supply to the lower limbs is different from manual observation of medical staff, the timeliness is good, lower limb ischemia complications can be recognized as soon as possible, data is provided for related scientific research of lower limb ischemia, the application prospect is good. Different from the mode that a lower limb far-end perfusion tube is punctured again to increase lower limb blood supply, the puncture frequency and puncture injury can be reduced, the occurrence rate of vascular complications is reduced and the pain of a patient is reduced.

A study was made on the therapeutic effect of midkine on an occlusive peripheral vascular disease, and it was found that midkine has an activity of promoting neovascularization and that a blood vessel can be proliferated and the blood flow in the upper and lower limbs can be improved (in other words, the condition of an ischemic disease in the upper and lower limbs can be ameliorated) by introducing midkine into a site affected by the occlusive peripheral vascular disease.

The invention relates to application of a lentivirus-mediated CXCR7 high expression engineered endothelial progenitor cell in treatment of ischemic diseases, discloses a nucleotide sequence shown as SEQ ID NO.1, and a recombinant virus and a transgenic cell containing the sequence. The invention also discloses application of the transgenic cell. The invention constructs the new recombinant lentivirus expressing CXCR7 and the transgenic endothelial progenitor cell containing the recombinant lentivirus, the cell has significantly improved transendothelial migration ability, and tests prove that the cell can effectively promote angiogenesis, treat diabetic diabetes caused lower limb ischemia and cerebral ischemia-reperfusion injury, and has good clinical application prospects.